These Top 2 Healthcare Companies Are in a Race to Riches

·6 min read
These Top 2 Healthcare Companies Are in a Race to Riches

For patients who go through the rigors of daily insulin shots to treat diabetes, the costs and logistics of adhering to a scheduled plan are a lot to keep up with. In 2020, two top healthcare companies performed admirably during phase 2 trials in a fight to help patients better manage diabetes. Novo Nordisk A/S (NYSE: NVO) and Eli Lilly (NYSE: LLY) both completed separate and successful phase 2 trials of new once-a-week insulin injection products that could potentially be game-changers in the insulin market for patients as well as investors.